Skip to main content
. Author manuscript; available in PMC: 2017 Oct 2.
Published in final edited form as: Adv Funct Mater. 2017 Sep 26;27(36):1701245. doi: 10.1002/adfm.201701245

Figure 7. Anti-tumor effects of nanodrugs functionalized with MeN1.

Figure 7

A) Anti-tumor effects of TNF and TNF-coated nanoparticles (Au/TNF) tagged with N1 or MeN1 alone or in combination (B) with MeN1-HSA, anti-CD13 mAb (R3-63) or control mAb (IgG2a), in the WEHI-164 fibrosarcoma model. MeN1-HSA was co-administered with N1/Au/TNF, whereas antibodies were given 2.5 h before the MeN1/Au/TNF.

C) Effect of MeN1– and ARA–liposomal doxorubicin (–Lipo[Doxo]) on tumor growth, animal weight and survival in the B16-F1 melanoma model.

Arrows, time of treatment; tumor volume (6 mice/group, mean ± SE). * (P < 0.05); ** (P < 0.01); *** (P< 0.001), by two-tail t-test (A-B) and log-rank (Mantel-Cox) test (C).